ProQR Therapeutics (PRQR) Total Liabilities (2021 - 2025)

ProQR Therapeutics (PRQR) has disclosed Total Liabilities for 5 consecutive years, with $73.8 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 13.04% to $73.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $73.8 million through Dec 2025, down 13.04% year-over-year, with the annual reading at $73.8 million for FY2025, 13.04% down from the prior year.
  • Total Liabilities hit $73.8 million in Q4 2025 for ProQR Therapeutics, down from $84.8 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $110.2 million in Q4 2021 to a low of $73.8 million in Q4 2025.
  • Historically, Total Liabilities has averaged $95.9 million across 5 years, with a median of $103.8 million in 2023.
  • Biggest five-year swings in Total Liabilities: decreased 2.75% in 2023 and later decreased 18.28% in 2024.
  • Year by year, Total Liabilities stood at $110.2 million in 2021, then fell by 3.14% to $106.8 million in 2022, then decreased by 2.75% to $103.8 million in 2023, then fell by 18.28% to $84.8 million in 2024, then dropped by 13.04% to $73.8 million in 2025.
  • Business Quant data shows Total Liabilities for PRQR at $73.8 million in Q4 2025, $84.8 million in Q4 2024, and $103.8 million in Q4 2023.